08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Merck KGaA cardiovascular, endocrine/metabolic news

Merck's Merck Serono S.A. unit said it will invest €80 million ($108.0 million) to open a 40,000 square meter pharmaceutical manufacturing facility in Shanghai, China. The company is slated to begin construction next year, complete...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Astellas, Toa Eiyo sales and marketing update

Toa Eiyo and Astellas launched once-daily Bisono Tape transdermal patch in Japan to treat hypertension. The product has a Japanese National Health Insurance (NHI) list price of ¥89.30 ($0.90) for the 4 mg patch and...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Bisono Tape regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) approved once-daily Bisono Tape transdermal patch from Toa Eiyo to treat hypertension. Nitto Denko and Tao Eiyo co-developed Bisono Tape, which contains 4 or 8 mg of...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

Maintate bisoprolol fumarate regulatory update

Mitsubishi said Japan approved a regulatory application to expand the label of Maintate bisoprolol fumarate tablets to include treatment of atrial fibrillation. The selective adrenergic receptor beta 1 ( ADRB1 ) antagonist is already approved...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

Maintate bisoprolol fumarate regulatory update

Mitsubishi submitted a regulatory application in Japan to expand the label of Maintate bisoprolol fumarate tablets to include treatment of chronic atrial fibrillation. The selective adrenergic receptor beta 1 ( ADRB1 ) antagonist is already...
07:00 , Mar 19, 2012 |  BioCentury  |  Strategy

Remaking Merck Serono

Five years after spending $13.2 billion to acquire Serono S.A. as a growth platform, Merck KGaA finds itself with much higher pharmaceutical sales than it could have achieved on its own, but no obvious way...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Daiichi Sankyo, Ranbaxy sales and marketing update

Ranbaxy received exclusive rights to distribute Daiichi's Congescor bisoprolol and Lopresor metroprolol in Italy. The beta blockers are approved to treat congestive heart failure (CHF) and hypertension, respectively. Terms were not disclosed. Daiichi acquired a...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Arrhythmia Store overload-induced Ca2 release (SOICR) In vitro and mouse studies suggest SOICR inhibitors could increase the efficacy of b-blockers to prevent ventricular arrhythmia....
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Recordati, Merck KGaA sales and marketing update

Merck granted Recordati rights to market Cardicor bisoprolol in Italy. The beta blocker is marketed to treat heart failure associated with reduced systolic ventricular function. Further terms were not disclosed. Recordati S.p.A. (Milan:REC), Milan, Italy...
07:00 , Jul 31, 2006 |  BC Week In Review  |  Company News

Biovail, Athpharma Ltd. deal

Biovail Corp. (TSX:BVF; BVF), Toronto, Ontario   Athpharma Ltd. , Athlone, Ireland   Business: Cardiovascular   The parties ended a 2003 deal in which BVF acquired four cardiovascular compounds from Athpharma: Bisochron bisoprolol, a beta...